Intervacc and the Swedish University of Agricultural Sciences, SLU, extends a multi-year contract for the development of innovative animal health vaccines

Stockholm, December 19th, 2022 - Intervacc AB (publ) and the Swedish University of Agricultural Sciences, SLU, announce today that they have extended the contract for the development of animal health vaccines using recombinant proteins. The successful collaboration has led to a vaccine against equine strangles approved by the European Medicines Agency, as well as promising vaccine candidates against other streptococcal and staphylococcal infections.

“Intervacc is very satisfied with the results that our research teams at SLU and KI have achieved together. We are convinced that more vaccines based on recombinant proteins will emerge from our ongoing collaboration. We are at the forefront of some very interesting animal health vaccine technologies, and we are excited about the ability to utilize this knowledge within vaccinology to bring new animal health vaccines to the market" – says Andreas Andersson, CEO Intervacc AB

The vaccine against equine strangles, approved by EMA and VMD, paves the way for a new generation of vaccines for bacterial infections. Based on the same technology platform, and with a focus on the same types of bacterial infections, Intervacc is developing more safe and effective vaccines. At the forefront of our development portfolio is a prototype vaccine against Streptococcus suis infections, one of the most serious infections affecting piglets, followed by a prototype vaccine against Staphylococcus aureus, which results in mastitis, a disease of the udder in dairy cows that is difficult to treat.

SLU is a world class research-focused university and Sweden's leading agricultural institution.  It includes an animal hospital and has facilities for animal and plant research as well as several other disciplines within the natural and social sciences. It offers 40 degree programmes and has over 3,500 students as well as 550 doctoral students. 

“I’m very pleased with the cooperation with Intervacc and we are excited to continue the work together with the development team. Together we are a leader in developing vaccines using recombinant fusion proteins, and we believe firmly that we are just at the beginning of this expanding field. This agreement confirms Intervacc and SLU’s long-term commitment to the project.” – says professor Bengt Guss, project leader at SLU.

Intervacc Chief Scientific Officer, Dr. Andrew Waller, summarizes “We are a unified research team with unique expertise and ability to deliver extraordinary results. It’s a great collaboration and this long-term agreement with SLU enables Intervacc to move forward with an increasingly strong pipeline of research and development opportunities for an expanded set of animal health vaccines.”

For more information please contact:  

Andreas Andersson, CEO

Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: [email protected]

The information was submitted for publication, through the agency of the contact person set out above on December 19, 2022, 16.00 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About SLU the Swedish University of Agricultural Sciences

SLU, the Swedish University of Agricultural Sciences, is a world-class international university with research, education and environmental assessment within the sciences for sustainable life. Its principal sites are in Alnarp, Umeå and Uppsala, but activities are also conducted at research stations, experimental parks and educational establishments throughout Sweden. We bring together people who have different perspectives, but they all have one and the same goal: to create the best conditions for a sustainable, thriving and better world. Please visit the website http://www.slu.se/ for more information.

 

About equine strangles

Equine strangles, caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.

 

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: [email protected], Phone: +46 (0)8 – 684 211 10